Slider Versus Tensioner Neural Mobilization in Diabetic Peripheral Neuropathy
Compare the Effects of Sliding With Tensioner Technique of Neural Mobilization in Diabetic Peripheral Neuropathy Patients
1 other identifier
interventional
32
1 country
1
Brief Summary
Neurodynamics, i.e., the mobilization of the peripheral nervous system, is a physical approach to the treatment of pain; the method relies on influencing pain physiology via mechanical treatment of neural tissues and the non-neural structures surrounding the nervous system. Neural mobilization (NM) is used to treat various disorders of the nervous system concerning the length and mobility of peripheral nerves, as the nerve mobilizing refers to techniques that help to reestablish motion between a nerve and its surrounding soft tissues, thus to treat the nerves that have become entangled within the soft tissue, as it leads to tension release on a nerve by stretching and pulling one end of the nerve during keeping the other end in a relaxed state.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jun 2022
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 15, 2022
CompletedFirst Posted
Study publicly available on registry
April 27, 2022
CompletedStudy Start
First participant enrolled
June 25, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
February 28, 2023
CompletedMarch 9, 2023
March 1, 2023
8 months
April 15, 2022
March 7, 2023
Conditions
Outcome Measures
Primary Outcomes (2)
Michigan neuropathy screening instrument
For screening the neuropathy; The MNSI questionnaire is self-administered. Responses are added to obtain a total score. 'Yes' responses to questions 1-3, 5-6, 8-9, 11-12, 14-15 are each counted as one point. 'No' responses to questions 7 and 13 each count as one point. Question 4 was considered to be a measure of impaired circulation and question 10 a measure of general asthenia and were not included in the published scoring algorithm. A score of ≥ 7 was considered abnormal. All 15 questions were included in the new scoring algorithms.
3 weeks
Numerical Pain Rating Scale
Quantify the pain ranging from 0 to 10 in which zero means no pain and 10 severe pain
3 weeks
Secondary Outcomes (1)
Quality of Life SF-36
3 weeks
Study Arms (2)
Group A
ACTIVE COMPARATORTENS, Stretching exercises, ROM exercises Sliding neural mobilization to femoral, sciatic, tibial nerve
Group B
ACTIVE COMPARATORTENS, Stretching exercises, ROM exercises Tensioner neural mobilization to femoral, sciatic, tibial nerve
Interventions
Sliding neural mobilization to femoral, sciatic and tibial nerve
Tensioner neural mobilization to femoral, sciatic and tibial nerve
Eligibility Criteria
You may qualify if:
- Patient having≥12score on Self report Leads Assessment of Neuropathic Symptoms and Sign
- Patients with lower limb pain ≥4 to ≤7 on NPRS
You may not qualify if:
- Diabetic foot ulcer
- Complex regional pain syndrome
- Infection in lower limb
- Lower extremity amputation
- Discogenic pain
- Restricted joint deformity
- Dependency on chemical or drugs
- Pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
DHQ Hospital
Mianwali, Punjab Province, Pakistan
Related Publications (4)
Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017 Jan;40(1):136-154. doi: 10.2337/dc16-2042. No abstract available.
PMID: 27999003BACKGROUNDIqbal Z, Azmi S, Yadav R, Ferdousi M, Kumar M, Cuthbertson DJ, Lim J, Malik RA, Alam U. Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy. Clin Ther. 2018 Jun;40(6):828-849. doi: 10.1016/j.clinthera.2018.04.001. Epub 2018 Apr 30.
PMID: 29709457BACKGROUNDFeldman EL, Nave KA, Jensen TS, Bennett DLH. New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. Neuron. 2017 Mar 22;93(6):1296-1313. doi: 10.1016/j.neuron.2017.02.005.
PMID: 28334605BACKGROUNDCho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018 Apr;138:271-281. doi: 10.1016/j.diabres.2018.02.023. Epub 2018 Feb 26.
PMID: 29496507BACKGROUND
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mirza Obaid Baig, MSPT(NMR)
Riphah International University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 15, 2022
First Posted
April 27, 2022
Study Start
June 25, 2022
Primary Completion
February 28, 2023
Study Completion
February 28, 2023
Last Updated
March 9, 2023
Record last verified: 2023-03
Data Sharing
- IPD Sharing
- Will not share